Eesti - eesti - Ravimiamet

ratiopharm gmbh - latanoprost - silmatilgad, lahus - 50mcg 1ml 2.5ml 1tk; 50mcg 1ml 2.5ml 6tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

paion deutschland gmbh - angiotensiin ii atsetaat - hypotension; shock - reniini-angiotensiini süsteemi toimivad ained - giapreza on näidustatud ravi tulekindlad hüpotensioon täiskasvanutel septiline või muu jae-ja šokk, kes jääb hypotensive vaatamata piisav maht tagastamise ja kohaldamise katehhoolamiinide ja muu kättesaadava ravi vasopressor.

Eesti - eesti - Ravimiamet

bausch + lomb ireland limited - travoprost - silmatilgad, lahus - 40mcg 1ml 2.5ml 4tk; 40mcg 1ml 2.5ml 1tk

Eesti - eesti - Ravimiamet

bausch + lomb ireland limited - timolool+latanoprost - silmatilgad, lahus - 5mg+50mcg 1ml 2.5ml 4tk; 5mg+50mcg 1ml 2.5ml 3tk; 5mg+50mcg 1ml 2.5ml 1tk

Eesti - eesti - Ravimiamet

bausch + lomb ireland limited - latanoprost - silmatilgad, lahus - 50mcg 1ml 2.5ml 1tk; 50mcg 1ml 2.5ml 3tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

santen oy - latanoprost, netarsudil mesilate - glaucoma, open-angle; ocular hypertension - oftalmoloogilised vahendid - roclanda is indicated for the reduction of elevated intraocular pressure (iop) in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient iop reduction.

Eesti - eesti - Ravimiamet

kalceks as - levosimendaan - infusioonilahuse kontsentraat - 2,5mg 1ml 5ml 4tk; 2,5mg 1ml 5ml 1tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - mitu müeloomit - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Euroopa Liit - eesti - EMA (European Medicines Agency)

astrazeneca ab - nirsevimab - suguhormoonid ja immunoglobuliinid, - beyfortus is indicated for the prevention of respiratory syncytial virus (rsv) lower respiratory tract disease in neonates and infants during their first rsv season. beyfortus should be used in accordance with official recommendations.

Euroopa Liit - eesti - EMA (European Medicines Agency)

roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - oftalmoloogilised vahendid - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).